- Investing Ideas
- /
- Hong Kong Pharmaceuticals & Biotech Leverage Leaders
Hong Kong Pharmaceuticals & Biotech Leverage Leaders
Results
19
19 companies
Sino Biopharmaceutical
Market Cap: HK$117.6b
An investment holding company, operates as a research and development pharmaceutical conglomerate in the People’s Republic of China.
1177
HK$6.83
7D
10.5%
1Y
127.7%
3SBio
Market Cap: HK$65.6b
An investment holding company, develops, produces markets, and sells biopharmaceutical products in Mainland China and internationally.
1530
HK$28.14
7D
16.4%
1Y
384.3%
TransThera Sciences (Nanjing)
Market Cap: HK$45.4b
TransThera Sciences (Nanjing), Inc., clinical stage biopharmaceutical company, discovers, develops, and commercializes small molecule therapies for oncology, inflammatory, and cardiometabolic diseases.
2617
HK$112.80
7D
-1.8%
1Y
n/a
WuXi Biologics (Cayman)
Market Cap: HK$140.8b
An investment holding company, provides end-to-end solutions and services for biologics discovery, development, and manufacturing for biologics industry in the People’s Republic of China, North America, Europe, Singapore, Japan, South Korea, and Australia.
2269
HK$36.12
7D
14.9%
1Y
119.2%
Simcere Pharmaceutical Group
Market Cap: HK$31.2b
An investment holding company, engages in the research, development, manufacture, and sale of pharmaceutical products to distributors, pharmacy chains, and other pharmaceutical manufacturers in China.
2096
HK$12.13
7D
1.3%
1Y
81.0%
Grand Pharmaceutical Group
Market Cap: HK$28.2b
An investment holding company, engages in the research and development, manufacture, and sale of pharmaceutical preparations and medical devices, biotechnology and healthcare products, and pharmaceutical raw materials.
512
HK$8.07
7D
2.8%
1Y
80.1%
China Medical System Holdings
Market Cap: HK$33.0b
An investment holding company, manufactures, sells, markets, and promotes pharmaceutical products in the People’s Republic of China.
867
HK$13.96
7D
8.2%
1Y
92.6%
United Laboratories International Holdings
Market Cap: HK$23.8b
An investment holding company, engages in the research and development, manufacture, distribution, and sale of pharmaceutical products.
3933
HK$11.98
7D
3.4%
1Y
2.9%
Sichuan Kelun-Biotech Biopharmaceutical
Market Cap: HK$102.8b
A biopharmaceutical company, engages in the research and development, manufacturing, and commercialization of novel drugs in oncology, immunology, and other therapeutic areas in the People’s Republic of China and internationally.
6990
HK$473.80
7D
20.8%
1Y
194.8%
Innovent Biologics
Market Cap: HK$145.4b
A biopharmaceutical company, engages in the research and development of antibody and protein medicine products in the People’s Republic of China, the United States, and internationally.
1801
HK$89.05
7D
16.8%
1Y
162.3%
Sunshine Lake Pharma
Market Cap: HK$25.2b
Engages in the research, development, manufacture, and sale of pharmaceutical products for the treatment of infectious diseases, chronic diseases, and oncology.
6887
HK$43.00
7D
-5.7%
1Y
15.7%
Duality Biotherapeutics
Market Cap: HK$30.2b
A clinical-stage biotech company, discovers and develops antibody-drug conjugate (ADC) therapeutics to treat cancer, autoimmune diseases, and others.
9606
HK$348.60
7D
16.9%
1Y
n/a
Hansoh Pharmaceutical Group
Market Cap: HK$233.6b
An investment holding company, engages in the research, development, production, and sale of pharmaceutical products in the People’s Republic of China.
3692
HK$40.04
7D
11.0%
1Y
146.9%
CSPC Pharmaceutical Group
Market Cap: HK$101.3b
An investment holding company, engages in the manufacture and sale of pharmaceutical products in Mainland China, other Asian regions, Europe, North America, and internationally.
1093
HK$9.12
7D
8.2%
1Y
106.3%
Genscript Biotech
Market Cap: HK$28.9b
An investment holding company, engages in the manufacture and sale of life science research products and services in the United States of America, Europe, Mainland China, Europe, Asia Pacific, and internationally.
1548
HK$13.77
7D
10.9%
1Y
46.2%
Keymed Biosciences
Market Cap: HK$16.7b
A biotechnology company, engages in the discovery and development of biological therapies in the autoimmune and oncology therapeutic areas in Mainland China and internationally.
2162
HK$58.45
7D
9.4%
1Y
108.8%
Shanghai Bao Pharmaceuticals
Market Cap: HK$23.6b
A clinical-stage biotechnology company uses synthetic biology technology to develop and deliver recombinant biologic drugs in Mainland China, Hong Kong, Macau, and Taiwan.
2659
HK$75.25
7D
-3.0%
1Y
n/a
InnoCare Pharma
Market Cap: HK$24.7b
A biopharmaceutical company, engages in discovering, developing, and commercializing drugs for the treatment of cancer and autoimmune diseases in China.
9969
HK$13.34
7D
8.5%
1Y
151.2%
WuXi XDC Cayman
Market Cap: HK$81.8b
An investment holding company, operates as a contract research, development, and manufacturing organization in China, North America, Europe, and internationally.
2268
HK$68.50
7D
12.8%
1Y
131.4%